The case against antipsychotic drugs: A 50-year record of doing more harm than good

Medical Hypotheses

Volumn 62, Issue 1, 2004, Pages 5-13

  Whitaker, Robert ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

BASAL GANGLION; BLINDNESS; BLOOD DISEASE; BRAIN CORTEX; BRAIN SIZE; BREAST DISEASE; BREAST TENDERNESS; CHRONIC DISEASE; CORRELATION ANALYSIS; DEINSTITUTIONALIZATION; DEVELOPING COUNTRY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; EVIDENCE BASED MEDICINE; GOOD CLINICAL PRACTICE; HEAT STROKE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMPOTENCE; LEAKING BREAST; LONG TERM CARE; MEDICAL RESEARCH; MENTAL HOSPITAL; NEUROLEPTIC MALIGNANT SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OUTPATIENT; PARKINSONISM; PRIORITY JOURNAL; PSYCHIATRIST; RASH; RELAPSE; REVIEW; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; THROMBUS; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; WORLD HEALTH ORGANIZATION;

EID: 1042300979     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00293-7     Document Type: Article

References (52)

1. Cole J, Klerman G, Goldberg S. The National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964;10:246-61.
2. Gilbert P, Harris M, McAdams L, Jeste D. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:173-88.
3. Shorter E. A history of psychiatry. New York: Wiley; 1997. p. 255.
4. Hegarty J, Baldessarini R, Tohen M, Waternaux C. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-16.
5. Holden C. Deconstructing schizophrenia. Science 2003; 299:333-5.
6. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(Suppl 11):53-60.
7. Harvey P. Cognitive impairment in schizophrenia: its characteristics and implications. Psychiatr Ann 1999;29: 657-60.
8. Stip E. Happy birthday neuroleptics! 50 years later: la folie du doute. Eur Psychiatry 2002;17(3):115-9.
9. Brill H, Patton R. Analysis of population reduction in New York State mental hospitals during the first four years of large scale therapy with psychotropic drugs. Am J Psychiatry 1959;116:495-508.
10. Brill H, Patton R. Clinical-statistical analysis of population changes in New York State mental hospitals since introduction of psychotropic drugs. Am J Psychiatry 1962;119:20-35.
11. Council of State Governments. The mental health programs of the forty-eight states. Chicago: The Council; 1950. p 4-13.
12. Rusk H. States map a new attack to combat mental illness. New York Times 1954;21:4-13.
13. Epstein L, Morgan R, Reynolds L. An approach to the effect of ataraxic drugs on hospital release rates. Am J Psychiatry 1962;119:36-47.
14. Scull A. Decarceration: community treatment and the deviant, a radical view. New Brunswick, NJ: Rutgers University Press; 1984.
15. Schooler N, Goldberg S, Boothe H, Cole J. One year after discharge:community adjustment of schizophrenic patients. Am J Psychiatry 1967;123:986-95.
16. Prien R, Levine J, Switalski R. Discontinuation of chemotherapy for chronic schizophrenics. Hosp Community Psychiatry 1971;22:20-3.
17. Gardos G, Cole J. Maintenance antipsychotic therapy: is the cure worse than the disease? Am J Psychiatry 1977;133: 32-6.
18. Bockoven J, Solomon H. Comparison of two five-year follow-up studies: 1947-1952 and 1967-1972. Am J Psychiatry 1975;132:796-801.
19. May P, Tuma A, Dixon W. Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981;38:776-84.
20. Carpenter W, McGlashan T, Strauss J. The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. Am J Psychiatry 1977;134:14-20.
21. Rappaport M, Hopkins H, Hall K, Belleza T, Silverman J. Are there schizophrenics for whom drugs may be unnecessary or contraindicated. Int Pharmacopsychiatry 1978; 13:100-11.
22. Mathews S, Roper M, Mosher L, Menn A. A non-neuroleptic treatment for schizophrenia: analysis of the two-year postdischarge risk of relapse. Schizophr Bull 1979;5:322-32.
23. Bola J, Mosher L. Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria Project. J Nerv Ment Dis 2003;191:219-29.
24. Chouinard G, Jones B, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978;135: 1409-10.
25. Chouinard G, Jones B. Neuroleptic-induced supersensitivity psychosis:clinical and pharmacologic characteristics. Am J Psychiatry 1980;137:16-20.
26. Leff J, Sartorius N, Korten A, Ernberg G. The International Pilot Study of Schizophrenia: five-year follow-up findings. Psychol Med 1992;22:131-45.
27. Jablensky A, Sartorius N, Ernberg G, Ansker M, Korten A, Cooper J, et al. Schizophrenia: manifestations, incidence and course in different cultures, A World Health Organization ten-country study. Psychol Med 1992;20(Monograph Suppl):1-95.
28. Gur R, Cowell P, Turetsky B, Gallacher F, Cannon T, Bilker W, et al. A follow-up magnetic resonance imaging study of schizophrenia. Arch Gen Psychiatry 1998;55: 145-52.
29. Chakos M, Lieberman J, Bilder R, Borenstein M, Lerner G, Bogerts B, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994; 151:1430-6.
30. Madsen A, Keiding A, Karle A, Esbjerg S, Hemmingsen R. Neuroleptics in progressive structural brain abnormalities in psychiatric illness. The Lancet 1998;352:784-5.
31. Gur R, Maany V, Mozley D, Swanson C, Bilker W, Gur R. Subcortical MRI volumes in neuroleptic-naïve and treated patients with schizophrenia. Am J Psychiatry 1998;155: 1711-7.
32. Hogarty G, Ulrich R. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998;32:243-50.
33. Baldessarini R, Viguera A. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52: 189-91.
34. Viguera A, Baldessarini R, Hegarty J, Van Kammen D, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54:49-55.
35. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 1994;89(Suppl 380):8-13.
36. Keefe R, Bollini A, Silva S. Do novel antipsychotics improve cognition? A report of a meta-analysis. Psychiatr Ann 1999; 29:623-9.
37. Arana G. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000;61(Suppl 8):5-13.
38. Kane J, Freeman H. Towards more effective antipsychotic treatment. Br J Psychiatry 1994;165(Suppl 25): 22-31.
39. Glazer W. Review of incidence studies of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000;61(Suppl 4):15-20.
40. Glazer W. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000;61(Suppl 4):21-5.
41. Ciompi L, Dauwalder H, Maier C, Aebi E, Trutsch K, Kupper Z, et al. The Pilot Project Soteria Berne. Br J Psychiatry 1992;161(Suppl 18):145-53.
42. Cullberg J. Integrating psychosocial therapy and low dose medical treatment in a total material of first episode psychotic patients compared to treatment as usual: a three-year followup. Med Arch 1999;53: 167-70.
43. Cullberg J. One-year outcome in first episode psychosis patients in the Swedish Parachute Project. Acta Psychiatr Scand 2002;106:276-85.
44. Lehtinen v, Aaltonen J, Koffert T, Rakkolainen V, Syvalahti E. Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? Eur Psychiatry 2000;15:312-20.
45. Lehtinen K. Finnish needs-adapted project: 5-year out-comes. Madrid, Spain: World Psychiatric Association International Congress; 2001.
46. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000;321:1371-6.
47. Liebzeit K, Markowitz J, Caley C. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11:25-32.
48. Goode E. Schizophrenia drugs may raise diabetes risk, study says. New York Times 2003;25.
49. Goode E. Pancreatitis risk seen in schizophrenia drugs. New York Times 2003;2.
50. Silvestri S, Seeman M, Negrete J, Houle S, Shammi C, Remington G, et al. Increased dopamine d2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 2000; 152:174-80.
51. McGuire P. New hope for people with schizophrenia. APA Monitor 2000;31 (number 2). Available from: http:// www.apa.org/monitor/feb00/schizophrenia. html.
52. Harding C, Zahniser J. Empirical correction of seven myths about schizophrenia with implications for treatment. Acta Psychiatr Scand 1994;90(Suppl 384):140-6.